Subject: Shingles (Zoster) Vaccine*

Effective Date: April 24, 2007

Department(s): Utilization Management

Policy: Live attenuated Varicella-Zoster Virus vaccine for prevention of herpes zoster is reimbursable under Plans administered by QualCare, Inc. consistent with the recommendations of the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention.

Objective: To provide proper and consistent reimbursement and to delineate criteria for coverage of a specific vaccine.

Procedure: A single dose of live attenuated Varicella-Zoster Virus vaccine (CPT 90736) is covered for adults 60 years of age and older, whether or not the individual has had a prior episode of herpes zoster.

References


Centers for Disease Control and Prevention. Recommended adult immunization schedule---United States, 2009. MMWR 2008;57(53) Q-1 – Q-4 (Jan 9, 2009)


Centers for Disease Control and Prevention. Recommendations for the Use of Zoster Vaccine. CDC Morbid Mortal Weekly Rep (scheduled for publication June 2007)


Quirk M. Routine shingles vaccine for US adults over 60. Lancet Infec Dis 2006;6(12):761 (Dec)


----- FDA Licenses New Vaccine to Reduce Older Americans’ Risk of Shingles. FDA News May 26, 2006

Approved By/Date: QM Committee 4/25/17

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.